Comparison of Efficacy and Safety of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol Combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in the Treatment of Moderate to Severe
Objective To compare the efficacy and safety of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in the treatment of patients with moderate to severe chronic obstructive pulmonary disease(COPD)during stable phase.Methods A total of 120 patients with moderate to severe COPD during stable phase admitted to the Lujiang People's Hospital of Anhui Province from March 2020 to February 2023 were selected and randomly divided into the control group and the study group by the random number table method,with 60 cases in each group.The patients in the control group were treated with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation,while the patients in the study group were treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.Both groups were treated for three months.Results The total effective rate and incidence of adverse reactions were comparable between the study group and the control group(86.67%vs.88.33%,11.67%vs.13.33%,P>0.05).After treatment,the lung function indexes such as the forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),the percentage of forced vital capacity to estimated value(FVC%),and the FEV1/FVC in the two groups significantly in increased(P<0.05),but there was no significant difference between the two groups(P>0.05);the arterial blood gas analysis indexes of arterial oxygen partial pressure(PaO2)and oxygen saturation(SaO2)in the two groups significantly increased(P<0.05),while the arterial partial pressure of carbon dioxide(PaCO2)in the two groups significantly decreased(P<0.05),but there was no significant difference between the two groups(P>0.05);the disease-related indexes such as the St.George's Respiratory Questionnaire(SGRQ)and COPD Assessment Test(CAT)scores in the two groups significantly decreased(P<0.05),the 6-Minute Walk Test(6MWT)in the two groups significantly extended(P<0.05),but there was no significant difference between the two groups(P>0.05);the levels of inflammatory factors such as C-reactive protein(CRP),interleukin-6(IL-6),and procalcitonin(PCT)in the two groups significantly reduced(P<0.05),but there was no significant difference between the two groups(P>0.05).Conclusion Both Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with Fluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation in the treatment of patients with moderate to severe COPD during stable phase have good and similar clinical efficacy and safety,they can effectively improve lung function and arterial blood gas indexes,and reduce inflammatory factor levels.In clinical practice,the two drugs should be selected based on the patient's disease characteristics and usage needs.
moderate to severe chronic obstructive pulmonary diseasestable phaseBudesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation AerosolFluticasone Furoate,Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalationefficacysafety
国家科技期刊平台
NSTL
万方数据
